Other substances

C2 (IgG)

An anti-RBD (SARS-CoV-2) neutralizing antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

C2 (IgG) is a human SARS-CoV-2-neutralizing antibody. It was created by reformatting a synthetic Fab which was selected for its affinity for SARS-CoV-2 Spike protein RBD using phage display into an IgG (Kim et al., 2021).

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library Spike protein Biophysical assay In vitro Antibody	in vitro binding assay; in vitro biophysical assay; HEK-293T cells expressing ACE2; Vero cells; SARS-CoV-2 Spike (D614G) pseudovirus; SARS-CoV-2 live virus (NCCP43326)	4.56	The antibody bound SARS-CoV-2 Spike RBD and neutralized SARS-CoV-2 pseudovirus and live virus with IC50s of 0.015 μg/mL and 0.018 μg/mL, respectively, in vitro.	Feb/15/2021

AI-suggested references

Link	Publication date
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.	Jun/28/2021
Glycomimetic ligands block the interaction of SARS-CoV-2 spike protein with C-type lectin co-receptors.	Apr/21/2022
Structural characterization and SARS-CoV-2 inhibitory activity of a sulfated polysaccharide from Caulerpa lentillifera.	Dec/21/2021
ORF3a-Mediated Incomplete Autophagy Facilitates Severe Acute Respiratory Syndrome Coronavirus-2 Replication	Nov/19/2020
Blocking key mutated hotspot residues in the RBD of the omicron variant (B.1.1.529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches.	Mar/04/2022
Nucleotide Analogues Bearing a C2' or C3'-Stereogenic All-Carbon Quaternary Center as SARS-CoV-2 RdRp Inhibitors	Apr/04/2021
Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2.	May/23/2021
The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship	Mar/30/2021
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19	Dec/01/2021
Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies	Jan/21/2021
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.	Jun/04/2021
The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.	Sep/24/2020

Export (.csv)